

2019 TAG ANNUAL REPORT

PROGRESS IN THE FIGHT

**For Better Treatment, Prevention,
A Vaccine, and a Cure for HIV,
Tuberculosis, and Hepatitis C Virus**

TAG

Treatment Action Group

June 2020

Dear Friend of TAG:

In these unprecedented times, I'm prouder than ever to share with you highlights from TAG's life-saving work. As you'll see in this *2019 Annual Report*, TAG achieved major victories in the struggle to end HIV, hepatitis C virus (HCV), and tuberculosis (TB) in the U.S. and around the world.

Despite an unfavorable political climate, TAG secured historic federal funding increases for research across all three disease areas, for programs to address domestic HIV and opioid-related infectious diseases including HCV, and for global TB programs. TAG's hard-hitting activism convinced the Food and Drug Administration (FDA) to hold Gilead accountable for not studying their new PrEP option in women. New York State and City, catalyzed by TAG and partners, are closer than ever to reaching ending the HIV epidemic targets. TAG launched the first-ever HCV diagnostics literacy program for community advocates. TAG's TB project's years of advocacy for research funding led to a landmark \$900 million in annual global TB research investments.

Your support makes us stronger. As we confront the challenges of 2020 head on—from accelerating the end of HIV, HCV, and TB to working tirelessly for a better response to COVID-19—we ask that you continue supporting our work, and thank you on behalf of everyone here at TAG.

Be safe, stay well, and thank you!

Yours in the struggle,



Barbara Hughes
President, Board of Directors

“ Your support makes us stronger. As we confront the challenges of 2020 head on—from accelerating the end of HIV, HCV, and TB to working tirelessly for a better response to COVID-19—we ask that you continue supporting our work, and thank you on behalf of everyone here at TAG.

2019 RESEARCH IN ACTION AWARDS

TAG's 2019 Research in Action Awards took place on November 14, 2019, at Town Stages in New York City. Our distinguished honorees this year were: **David France**, Oscar-nominated filmmaker, *New York Times* best-selling author, award-winning investigative journalist, and director of *How to Survive a Plague* and *The Death and Life of Marsha P. Johnson*; **Matthew Lopez**, Olivier Award-winning playwright/screenwriter and author of the play, *The Inheritance*; **Amanda Lugg**, long-time activist and Director of Advocacy and LGBT Programming at African Services Committee; and **Dr. John 'Jack' Steever**, Assistant Professor of Pediatrics, The Mount Sinai Adolescent Health Center, Mount Sinai Medical Center, specializing in HIV prevention and treatment in young LGBTQ people. **Tom Kirdahy**, Broadway producer, attorney, and human rights advocate was our honorary event chair. All photos by Alan Barnett Photography.



Honoree **Matthew Lopez** with honorary event chair, Broadway Producer and activist **Tom Kirdahy**.

(center) Honoree **Amanda Lugg**, doing what she does best: inspiring the masses.



Two of our generous creators of previous Limited Art Editions **Carrie Yamaoka**, 2007's *25/Blues*, and **Erica Baum**, 2017's *Peer*.



Honoree **Dr. Jack Steever** addresses RIAA participants after accepting his award.



Honoree **David France** with RIAA 2019 co-host **Ron Goldberg**.



Three of TAG's wonderful board members (from left to right): **Kevin Goetz**; **Joy Episalla** (who manages our Limited Art Editions); and board president, **Barbara Hughes**.

TAG ANNUAL REPORT PROJECT UPDATES

HIV PROJECT

In 2019, TAG advanced our life-saving work of ensuring progress on research toward improved HIV prevention and a cure, and accelerating the end of HIV as an epidemic. At the start of the year, the President announced the Ending the HIV Epidemic initiative to first stop new transmissions in 57 jurisdictions, and eventually bring the whole nation below epidemic levels by 2030. This initiative presents a huge opportunity, while highlighting several crucial gaps. TAG supported the ACT NOW: END AIDS Coalition, of which we are a co-founder, in delineating core community principles needed to actually end the epidemic for everyone in the U.S. These core principles are especially important for vulnerable populations who are threatened by other administration policies. To ensure that jurisdictional plans to end the epidemic reflect community priorities, we took the lead in launching a new ACT NOW: END AIDS Coalition initiative to support community organizations representing some of the hardest hit communities to participate in their local Ending the HIV Epidemic planning. In New York, we continued to advance the end of the HIV epidemic, celebrating progress—including a 28% drop in new diagnoses in New York State between 2014 and 2018—while also calling attention to key unmet needs, including accessible prevention and testing for young people of color and transgender communities.

We fought back against unfair pricing and access policies that threaten the ability to end HIV. As you'll read more about in our Policy update, we submitted testimony to Congress on the need to reduce the high price of pre-exposure prophylaxis (PrEP). We pushed back against the U.S. government's plan to pay Gilead millions of dollars to distribute its own product as part of the *Ready, Set, PrEP* program, and supported a rejection of Gilead's claims over PrEP patents resulting from government-funded research. TAG led a group of eight HIV research and advocacy groups in filing a friend-of-the-court brief in support of the plaintiffs in *Staley v. Gilead*, who filed suit against four drug companies for price-fixing and keeping generic drugs off the market.

TAG pushed the U.S. Food and Drug Administration (FDA) to hold a public hearing on Gilead's application for approval of their new PrEP option to review lack of inclusion of key populations in research, lack of transparency, and the need for a clear generic pathway. Our testimony and that of partners led to the FDA requiring further research in individuals at risk for vaginal exposure to HIV, including cisgender women and transgender men.

Furthering community-inclusive research, TAG launched a survey on community perspectives on the future of HIV prevention trials. We led an analysis of HIV cure-related clinical trials in 2019, publishing findings that highlight important issues, such as the continuing underrepresentation of women in cure research. TAG's Cure Research Media Monitor tracked progress on HIV cure research and debunked myths, and our first-ever *Pipeline Report* on sexually transmitted infections analyzed prospects and needs for improving prevention and treatment for gonorrhea, chlamydia, and syphilis.

TAG's 2019 HIV Publications

- *Gene Editing in HIV Research*
- *A Landscape Analysis of HIV Cure-Related Clinical Trials in 2018*
- *Pipeline for Gonorrhea, Chlamydia, and Syphilis*
- *Antiretroviral Therapy Pipeline*
- *HIV Vaccines, Passive Immunization, and Antibody Gene Transfer Pipeline*
- *Research Toward a Cure and Immune-Based Therapies Pipeline*
- *From Engagement to Leadership: Placing Community Priorities at the Heart of HIV Prevention Research* (TAGline May 2019)
- *Scientific Complexity and Ethical Uncertainties: The Importance of Community Engagement in HIV Cure Research* (TAGline May 2019)
- *Dispatches from the War on Science* (TAGline November 2019)
- *Centering Intersectional Movement Building in 2020 Election HIV Advocacy: Guidance from Movement Leaders* (TAGline November 2019)

POLICY PROJECT

TAG's policy team achieved historic wins in 2019 towards ending HIV, tuberculosis (TB), and hepatitis C virus (HCV). In the final budget passed by Congress and signed by the President in December 2019, TAG and our partners secured FY20 federal funding increases for global TB programs and research (\$8 million increase), HIV research (\$25 million increase), opioid-related infectious disease lines (\$5 million increase), HCV vaccine research (\$8 million), and new initiatives under the administration's Ending the HIV Epidemic goals (\$140 million increase).

We influenced policy and legislation to improve access to medicines. Our input to Speaker Pelosi's office strengthened and broadened drug pricing reforms in the Elijah E. Cummings Lower Drug Costs Now Act, which the House passed. TAG was specifically called upon by the House Committee on Oversight and Reform to submit testimony for a Congressional hearing investigating Gilead's high pricing of Truvada for PrEP. Preparing for the 2020 election cycle within parameters permissible for 501(c)3 organizations, TAG and the ACT NOW: END AIDS Coalition engaged with 2020 presidential candidate campaign offices about their platforms and policy plans to end the HIV epidemic.

To advance efforts to end TB, TAG co-organized a Congressional briefing and a series of advocacy trainings to build capacity for legislative campaigns. These collaborative efforts resulted in new bipartisan Congressional endorsements for the Comprehensive TB Elimination Act (which includes provisions for research as well as domestic TB programs), and the introduction of the End TB Now Act (which supports global TB programming and research). Under a new partnership with the National TB Controllers Association, TAG continued to support a cutting-edge TB response in New York, and launched community engagement initiatives in Indiana, Los Angeles County, and Louisiana to support those and other jurisdictions' efforts to end TB. Policy staff advanced the concept of "fair share" funding targets for TB research,

building awareness in the White House Office of Management and Budget, the State Department, and the Department of Health and Human Services, and cultivating buy-in from key federal agencies involved in TB research to hit the U.S. target.

Back in New York, TAG advanced the end of HCV in the state by working with the Surveillance, Data, and Metrics working group of the New York State HCV Elimination Task Force to generate recommendations for the governor, and serving on the Elimination Metrics Advisory Committee to guide the development and monitoring of HCV elimination metrics and progress. In parallel, we initiated a community engagement and advocacy initiative toward viral hepatitis elimination in New York City, coordinating a series of borough events. TAG helped build a citywide coalition in response to deep cuts under Article 6 State matching funds to New York City health programs. This emerging coalition successfully restored \$65 million through reallocation of New York City general funds.

We also welcomed the newest junior member of our policy team, Saurav Madoori, baby of proud parents Suraj Madoori (TAG's Director of U.S. & Global Health Policy) and Shivani Thaker.

TAG's 2019 Policy Publications

- *Closing the Gap in Tuberculosis Research and Development Funding Briefs (for Legislative & Executive Agencies)*
- *Act Up. Fight Back. Fight TB: Potential Pathways to R&D Funding Advocacy for the U.S. TB Community* (TAGline May 2019)
- *Regime Change in America: Tracking TAG's Work Across Eight National Election Cycles* (TAGline November 2019)
- *Centering Intersectional Movement Building in 2020 Election HIV Advocacy: Guidance from Movement Leaders* (TAGline November 2019)
- *This Is Not a Drill: Science, Solidarity and the 2020 Elections* (TAGline November 2019)

HCV PROJECT

TAG's groundbreaking HCV community engagement and advocacy initiatives in 2019 achieved notable global policy wins. Our actions helped ensure that outcome documents from the United Nations High-Level Meeting on Universal Health Coverage included addressing viral hepatitis. TAG provided vital feedback to raise the importance of hepatitis C activities and

“Furthering our technical support for advocates around the world, TAG disseminated critical information and capacity building materials.

to promote harm reduction in the U.S. President's Emergency Plan For AIDS Relief (PEPFAR) guidance to countries. This feedback

resulted in tripling the number of mentions for viral hepatitis in the final PEPFAR guidance released in 2020, which could provide opportunities to integrate hepatitis in country programs.

In partnership with the Foundation for Innovative New Diagnostics (FIND), our HCV Project launched an in-depth diagnostics literacy program for 75 advocates in the countries of Georgia and Malaysia—the first, to our knowledge. Partnering with FIND, the Georgian Harm Reduction Network, and the Georgian Community Advisory Board, TAG provided technical capacity building among community leaders and harm reductionists. Monitoring policy changes continues through a newly formed, community-led steering committee and stronger relationships with the Georgian Ministry of Health. Advocacy workshops with the Positive Malaysian Treatment Access and Advocacy Group, medical providers, and grassroots leaders from drug user, LGBTQ+, and sex worker activist communities, helped make community engagement and decentralized testing integral components in Malaysia's elimination strategy.

Furthering our technical support for advocates around the world, TAG disseminated critical information and

capacity building materials. We expanded our crowd-sourced data platform, mapCrowd, to include country-specific information on the latest generic hepatitis C medications and diagnostics. We partnered with Harm Reduction International to integrate data on harm reduction coverage, treatment restrictions, and inclusion of people who use drugs in national strategies. Our collaboration enabled analysis of new data from high-burden countries, including Iran, Nigeria, the Philippines, and Uzbekistan. TAG, the global hepCoalition network (of which we are a co-founder), and partners launched hard-hitting campaigns and fact sheets in multiple languages to assist communities and inform policymakers on progress made towards HCV elimination. The community checklist, *Who Counts in Our National Hepatitis Plans?*, the *Comprehensive HCV Package of Services for People Who Use and Inject Drugs* infographic, and *Have A Heart, Save My Liver!* diagnostics brief have been used by partners to inform community trainings and high-level policy meetings in Georgia, India, Malaysia, Lao People's Democratic Republic, South Africa, and Tanzania.

TAG spearheaded another campaign, challenging human rights abuses and calling for the release of three detained HIV/HCV lawyers and activists in Changsha, China. This campaign raised awareness among over 15,000 people on social media. TAG campaigned to increase programming and funding for people with HIV/HCV coinfection through the Global Fund to Fight AIDS, Tuberculosis, and Malaria, and continues to advocate for expanded access to generic hepatitis C medications by AbbVie, Gilead, and licensed generic manufacturers.

TAG's 2019 HCV Publications

- *New HCV Fact Sheets for sofosbuvir/daclatasvir and Mavyret (glecaprevir/pibrentasvir)*
- *Activist Guide to Hepatitis C Virus Diagnostics and training curriculum slide deck*
- *HCV Diagnostics Pipeline*
- *HCV Treatment Pipeline*
- *Love Trumps Hate: Building People Power and Reshaping Political Struggles Toward Harm Reduction, Humanity, and Hope* (TAGline November 2019)

TB PROJECT

TAG's TB project achieved several victories for TB research and access in 2019. Our decades of TB research funding advocacy have been bearing fruit—our signature report showed that global funding for TB research and development reached a new all-time high in 2018 of over \$900 million. The World Health Organization (WHO) incorporated TAG-developed targets for country funding into their Global Strategy for TB Research and Development, and the U.S. government announced meeting its TAG-set target.

TAG's research advocacy, community engagement efforts, and participation in trial design also contributed to the launch of important studies and the defense of rigorous TB science. A much-anticipated trial from the National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group to test a newer drug's ability to prevent drug-resistant TB started. TAG testified before the FDA regarding pretomanid, a new TB drug, to express concern regarding remaining research questions, and the importance of upholding stringent evidentiary standards for new TB medicines. The TAG-coordinated Community Research Advisors Group (the community advisory board to the Centers for Disease Control and Prevention's Tuberculosis Trials Consortium) proposed a qualitative study of barriers and facilitators to enrolling adolescents in TB treatment trials; this study also began in 2019.

Our advocacy to ensure that advances of science translate into sound policy similarly achieved success. TAG and partners' advocacy for WHO guideline changes and participation in guidance development secured life-saving updates. WHO guidance now strongly recommends molecular diagnosis for TB for all, and less toxic, more effective, all-oral regimens for treating drug-resistant TB. As with our HCV project, our TB project successfully influenced PEPFAR's guidance to countries to promote better TB diagnostics and treatments in global AIDS programs, including TB preventive therapy, pediatric TB interventions, and molecular and rapid TB tests.

To facilitate uptake of evidence-based interventions to end TB, TAG's TB project advanced several campaigns to increase access to essential TB medicines (bedaquiline, pretomanid, delamanid, and rifapentine) and diagnostics (GeneXpert). These campaigns centered on technologies developed with public and philanthropic funding, but manufactured and sold by companies at unaffordable prices.

Through all this work and more, our TB project engaged and empowered community advocates. Our advocacy workshops on preventive therapy and pediatric TB supported activists in over 15 countries to call for access to preventive therapy and pediatric TB interventions.

We held the first cross-training between TB activists (represented chiefly by the TAG-supported Global TB

Community Advisory Board) and access to medicines activists, to foster common understanding, solidarity, and stronger campaigns to improve access to TB commodities.

Our advocacy to ensure that advances of science translate into sound policy similarly achieved success.

TAG's 2019 TB Publications

- *TB LAM Testing Briefs*
- *An Activist's Guide to Rifapentine for the Treatment of TB Infection*
- *2019 Report on TB Research Funding Trends*
- *National TB Checklist Update*
- *TB Activist Toolkits Update*
- *Pediatric Tuberculosis Diagnosis, Treatment, and Prevention Pipeline*
- *TB Diagnostics Pipeline*
- *TB Treatment Pipeline*
- *TB Vaccines Pipeline*
- *Sound Off: Three Activists Reflect on Community Victories and Priorities in TB Research* (TAGline May 2019)
- *The Final Frontier: Breaking Down Barriers to Community Engagement in Diagnostics Research* (TAGline May 2019)

Balance Sheet

	2019	2018
Assets		
Cash and cash equivalents	\$1,610,906	\$1,534,231
Unconditional Promises to Give	496,981	1,216,871
Accounts receivable	7,583	1,139
Prepaid expenses and other current assets	37,208	31,594
Donated artwork	492,739	439,739
Security deposit	72,463	72,463
Property and equipment - net	18,580	26,728
Total Assets	\$2,736,460	\$3,322,765
Liabilities and Net Assets		
Liabilities		
Accounts payable and accrued expenses	\$38,603	\$25,396
Deferred rent	33,362	42,520
Total Liabilities	71,965	67,916
Net Assets		
Without donor restrictions	1,537,543	1,736,034
With donor restrictions	1,126,952	1,518,815
Total Net Assets	2,664,495	3,254,849
Total Liabilities and Net Assets	\$2,736,460	\$3,322,765


Statement of Cash Flows

	2019	2018
Cash Flows from Operating Activities		
Increase (decrease) in net assets	(\$590,354)	(\$701,749)
Adjustments to reconcile increase (decrease) in net assets to net cash used by operating activities:		
Depreciation	9,547	10,873
(Increase) decrease in:		
Unconditional promises to give	719,890	333,023
Accounts receivable	(6,444)	(1,139)
Prepaid expenses and other assets	(5,614)	(6,210)
Donated artwork	(53,000)	(25,239)
Increase (decrease) in:		
Accounts payable and accrued expenses	13,207	(264)
Deferred rent	(9,158)	(12,549)
Net Cash Used by Operating Activities	78,074	(403,254)
Cash Flows from Investing Activities		
Acquisition of property and equipment	(1,399)	(11,627)
Proceeds from sales of fixed assets	-	-
Net Cash Used by Investing Activities	(1,399)	(11,627)
Net decrease in cash and cash equivalents	76,675	(414,881)
Cash and cash equivalents, beginning of year	1,534,231	1,949,112
Cash and Cash Equivalents, End of Year	\$1,610,906	\$1,534,231

Statement of Activities

	2019		
	Without Donor Restrictions	With Donor Restrictions	Total
Revenue and Other Support			
Contributions	\$277,143	\$1,484,565	\$1,761,708
Fundraising benefit events	287,848	-	287,848
Less: Direct benefit expenses	(79,422)	-	(79,422)
Donated artwork, goods and services	174,796	-	174,796
Art sales, net of cost of goods sold	500	-	500
Other income	27,413	-	27,413
Interest income	1,347	-	1,347
Net assets released from restrictions	1,876,428	(1,876,428)	-
Total Revenue and Other Support	2,566,053	(391,863)	2,174,190
Expenses			
Program Services			
HIV Program	590,447	-	590,447
Hepatitis C Virus Program	307,575	-	307,575
TB/HIV Program	1,246,647	-	1,246,647
Total Program Services	2,144,669	-	2,144,669
Supporting Services			
Management and general	379,723	-	379,723
Fundraising	240,152	-	240,152
Total Expenses	2,764,544	-	2,764,544
Increase (decrease) in net assets	(198,491)	(391,863)	(590,354)
Net assets, beginning of year	1,736,034	1,518,815	3,254,849
Net Assets, End of Year	\$1,537,543	\$1,126,952	\$2,664,495

Summary of 2019 Functional Expenses



\$100,000 or more

The Aurum Institute
 Bill and Melinda Gates
 Foundation
 Viiv Healthcare

\$50,000 to \$99,999

Broadway Cares / Equity
 Fights AIDS
 Foundation for Innovative
 New Diagnostics
 Elizabeth Glaser Pediatric
 AIDS Foundation
 Global Drug Facility via Stop
 TB Partnership
 Stop TB Partnership hosted
 by UNOPS
 Joy A. Tomchin
 Veterans Affairs Medical
 Center of Washington, DC

\$25,000 to \$49,999

The Debs Foundation: Richard
 A. and Barbara Knowles
 Debs; Nick Debs
 Hauser & Wirth
 Fred Hutchinson Cancer
 Research Center
 M•A•C AIDS Fund
 Merck & Co.

\$10,000 to \$24,999

amfAR, The Foundation for
 AIDS Research
 Michael Becker and Tee
 Scatuorchio
 Annie Bennett Glenn Fund in
 honor of P. Forrest Williams,
 Jr.
 Kevin and Neil Goetz / Screen
 Engine/ASI
 The Great American
 Songbook Foundation
 The Hepatitis C Mentor and
 Support Group
 Marta Heflin Foundation
 Bobby McLain and Alberto
 Blanquel

\$5,000 to \$9,999

The Calamus Foundation
 JPMorgan Chase Foundation
 in recognition of TAG Board
 member Richard Lynn
 Celeste B. Cooper
 David Corkery
 The Gendal Family
 Foundation in honor of
 Monte Steinman
 Richie Jackson and Jordan
 Roth
 Janssen Therapeutics
 Jameel Jiwani
 Robert W. Lennon and Mark
 Gilrain
 Richard M. Lynn and Joseph
 Evall
 Médecins du Monde
 Robert Monteleone
 Laura A. Morrison
 National Coalition of STD
 Directors
 National TB Controllers
 Association
 Marc Wolinsky and Barry C.
 Skovgaard

\$2,500 to \$4,999

1199 SEIU
 Abbott Laboratories
 Jim Aquino
 Jeff D. and Michelle Kleinert
 Bader
 Bob Bronzo
 Dr. Joseph Burzynski
 Cristopher Canizares
 Benson Cohen
 John F. Duane and Mary E.
 Northridge
 Marc E. Elovitz in honor of
 Richard Lynn and Joseph
 Evall
 David France
 Suzanne Gay and Bryn M. Gay
 in memory of Phillips G.
 Gay, Jr.
 Judith and Richard Harrington
 Paula Hartstein
 Barbara F. Hughes
 Noel E.D. Kirnon and Michael
 D. Paley

Ivy Kwan Arce in memory
 of Sally C. Cooper, Karina
 Haslip, and Michael Callen
 Dr. J. Michael McCune III
 and Dr. Karen Kaye Smith-
 McCune
 Eddie Pelto in memory of
 Daniel A. Volpe, Jr.
 Bruce Schackman and Ed
 Sikov
 Jeff Schoenfeld and Matt
 Holbein
 Bill Shea and Frank Selvaggi
 The Sigal Family Foundation:
 David Sigal and New York
 State Senator Brad Hoylman
 Mrinal Vikram and Kevin
 Finnegan
 John Voelcker
 Weil, Gotshal & Manges LLP
 The Andrew D. Zacks
 Foundation

\$1,000 to \$2,499

Amida Care / Doug Wirth
 Katherine C. and Thomas M.
 Ash III in memory of Richard
 Harrington
 AVAC / Mitchell Warren
 Jack M. Battaglia
 Erica Baum
 Michael Bennett in memory of
 Ty French
 Karen Bronzo and Jefferson
 Rabb
 Brooklyn Community
 Foundation
 Steven F. Capone
 Lawrence Corey, MD
 Jonathan Creighton and
 Megan Harrington
 Michael Cunningham and Ken
 Corbett
 Dick Dadey
 Arianne Z. Dar / New Ground
 Fund of Marin Community
 Foundation
 Hon. Thomas K. Duane
 Kimberly Elliott in honor of
 Jane Silver
 Ruth Finkelstein and BC Craig
 Bruce C. Francis in memory of
 Rich DeNagel

Fung Chun Bong
 Jennifer J. Furin, MD, PhD
 Robert Gillard and James
 Harrington in honor of
 Monte Steinman
 David Gold
 David Greenblatt
 Mark Harrington
 Christina and Kenneth Hecht
 in memory of Richard
 Harrington
 Hon. James C. Hormel
 Housing Works / Charles King
 IAVI / Dr. Mark Feinberg, CEO
 Tom Kirdahy and the late
 Terrence McNally in
 memory of Gary Bonasorte
 Emmy Kondo and Danny
 Rosenthal
 Jay Leitz
 Michael K. Longacre in
 memory of Tony Ortiz
 Alby P. Maccarone, Jr.
 Loring McAlpin
 Albert S. Messina and
 Kenneth L. Jennings in
 honor of our friend Richard
 Jacobs
 George J. and Mirla N.
 Morrison
 Craig Murray in honor of Kevin
 and Neil Goetz
 Otsuka Novel Products GmbH
 Marvel S. Platoff Foundation
 Kevin Ryan
 Andrew C. Schirrmeister III in
 honor of Monte Steinman
 Evan Schwartz and Robert
 Fitterman
 H.A. 'Hal' Sedgwick in honor
 of Cassandra Leveille
 Kurt R. Soderlund
 Rachel B. Tiven and Seth M.
 Marnin
 W. Kirk Wallace and Mark M.
 Sexton
 Thomas P. Wilczak and Steven
 R. Quinkert
 Nadine Witkin

\$500 to \$999

AIDS Action Baltimore
 Association of State and Territorial Health Officials
 Robert J. and Margot Bazell
 Michael Beltran and Timothy Ford
 Peter F. Brown and Dr. Margaret Hamburg
 Steven J. and Denise Chickery
 Michael Coady
 Robert N. Croonquist
 Alan Cumming and Grant Shaffer
 Paul L. Dietz
 Eric Eidelman and Julie A. Mirolla
 Stephen A. Foster
 Steven M. Frank and Dr. Elizabeth S. Powell
 New York State Assembly Member Deborah J. Glick
 GMHC / Kelsey Louie
 God's Love We Deliver
 Roy M. 'Trip' Gulick, MD
 Health GAP
 Alex Henderson and Oskar Moguel
 Robert C. Henry
 Drew Hodges and Peter Kukielski
 Tim Hosking and Audrey Sokoloff in honor of Rich Lynn for his many and continuing efforts on behalf of TAG
 Michael T. Isbell in memory of Spencer Cox
 Richard Jefferys in memory of Richard Harrington
 Preston Kennedy in honor of those who have passed and those still fighting
 Paul Kennedy
 Babette Krolik and Sara Rafsky
 Burt R. Lazarin
 Justin D. Lee and Michael E. Gunther
 David C. Levine
 Joseph McConnell and Erik Haagensen

Jeff Mendoza and Dr. Chuck Sklar
 Sally Morrison in honor of Dr. Lucy Painter
 Mount Sinai Institute for Advanced Medicine
 John Nesbit and Cristina Corbin
 Kim Nichols in honor of Amanda Lugg
 Natalie Olstein in memory of Bobby Rosenthal, to honor his mother Suzanne Benzer on her 80th birthday; a gift from her friends
 Jason Osher and Richard Schubel
 Daniel Ptacek
 Robert H. Remien
 Walter Rieman in memory of Tom Stoddard
 Roche / Robin Thomas
 Jamie Saakvitne and Daniel Chow in honor of Dr. John B. Steever
 Greig Sargeant
 Lyle Saunders in honor of Laura Morrison
 Peter A. Schamel
 Sarah F. and Roy E. Schutzengel in memory of Hartly Fleischmann
 Stephan Shaw and Sunita Viswanath
 David R. Shaw and Francesca Zaccheo
 Andrew Shih
 Virginia Shubert and David Sipress
 Jane Silver
 Peter Staley
 Monte Steinman
 Marc Szafran
 Cathy E. Taub and Lowell C. Freiberg
 Keith S. Tobin, MD
 Dennis Trunfio
 Paolo Danilo Vicino
 Lisa Volling in honor of Jameel Jiwani
 P. Forrest Williams, Jr.

\$250 to \$499

Michele Araujo
 Joe Baker in honor of Tom Kirdahy, for the Opening of "The Inheritance"
 Alvin Baum in memory of Richard Harrington of San Francisco, father of Mark Harrington
 Robert Beatty in honor of Monte Steinman
 Danielle Berz in honor of Jameel Jiwani
 Jessica Boyle
 Richard Cardillo in memory of Peter F. Diffly, Jr.
 Dr. Charles C.J. Carpenter and Mrs. Sally F. Carpenter
 Patricia Costello in memory of Jim Konetsky
 Scott Dainton
 Judith Davis-Fagan
 Lynda Dee, Esq.
 Peter Morris Dixon
 Jim Eigo
 Jennifer Eisenstadt in honor of Dr. John Steever
 Paula Elbrit in honor of Dr. John B. Steever
 Monica Gerber
 Leslie Asako Gladsjo
 Ron Goldberg
 Joy Harris
 Drew Hodges in honor of Tom Kirdahy, for the Opening of "The Inheritance"
 Kevin Jennings and Jeff Davis in honor of David France
 Jay Johnson and Thomas Cashin
 Hooman Kamel in honor of the PrEP4All Collaboration
 Jeremy Kawaller
 Sung Woon Kil in honor of Bob Bronzo
 James Krellenstein
 Joseph Lauretano
 Charles S. Laven
 Susan Leimsider in honor of Erica Lessem
 Claire Lennon
 Margaret Lennon

Linda Liedtka
 Mayo Schreiber
 Merle C. McCann MD in memory of John Stuban
 Fernando J. Alva Miras
 Joseph S. Monteleone
 Fraser D. 'Skip' Mooney
 Dr. Steven S. Muchnick and Eric Milliren
 Scott Newman
 Ann Northrop
 Kathleen O'Leary in honor of Bob Bronzo
 Stephanie Oster
 Pam Parker
 Laura Pinsky in memory of Rich DeNagel
 Sheila Reeves
 Clifford Richner
 Erica Rosengart
 Kimberleigh Smith in honor of Amanda Lugg
 Robin Thomas
 Oliver R. Tobin
 Barbara Toll in honor of Jeff Mendoza
 Christian Urrutia

plus donations from an additional **195** generous contributors, including Anonymous gifts

We would also like to thank those who gave generously to TAG as part of campaigns hosted via Act Blue Charities, PayPal Charitable Giving (for Board member Jim Aquino's participation in the Boston Marathon), and Network for Good (Board member Eddie Pelto's FaceBook campaign). TAG was the beneficiary of funds raised as part of the 2019 NYC AIDS Walk, and through participation in the Amazon Smile program. TAG would like to thank artist Glenn Ligon, Print Positive NY, SpotCo, and Board members Kevin Goetz and Jeff Mendoza for their generous in-kind donation of goods and services, to support fundraising events that benefitted TAG.

About TAG

Treatment Action Group (TAG) is an independent, activist and community-based research and policy think tank fighting for better treatment, prevention, a vaccine, and a cure for HIV, tuberculosis, and hepatitis C virus.

TAG works to ensure that all people with HIV, TB, or HCV receive lifesaving treatment, care, and information.

We're science-based treatment activists working to expand and accelerate vital research and effective community engagement with research and policy institutions.

TAG catalyzes open collective action by all affected communities, scientists, and policy makers to end HIV, TB, and HCV.

Support TAG

In 2019, TAG made many strides against HIV, HCV, and TB. In 2020, we continue our vital core work to end HIV, HCV, and TB, while applying our expertise to the COVID-19 pandemic. A robust response based on science and driven by community priorities is more crucial than ever.

Make a gift to TAG and help us advocate for the needs of all people affected by HIV, HCV, TB, and COVID-19.

Support TAG today: www.treatmentactiongroup.org/support.

Does your organization have a matching gifts program? Don't miss your chance to make a gift that keeps on giving. Complete and send us your company's matching gift form to double your contribution's impact!

Thank You, Board Members

The Board and Staff of Treatment Action Group thanks Bobby McLain, Jeff Mendoza, and Monte Steinman for their years of dedicated and significant service on TAG's Board of Directors.

TAG Limited Art Editions

Each year at its Research in Action Awards, TAG presents a new, limited edition work of art. Past artists include Glenn Ligon, Zoe Leonard, Erica Baum, Rosalind Fox Solomon, Joy Episalla, Kate Shepherd, Nan Goldin, Robert Gober, Bill Jacobson, fierce pussy, Donald Moffett, Tony Feher, Carrie Yamaoka, David Armstrong, and Richard Renaldi.

TAG retains an inventory of many of the editions for sale to the public, and all proceeds benefit TAG's work. If you're interested in purchasing an edition or learning more about the available editions, detailed information can be found at <http://www.treatmentactiongroup.org/limited-art-editions>.



Glenn Ligon *Black Rage* (back cover), 2019

2020 BOARD OF DIRECTORS

PRESIDENT: Barbara Hughes

VICE PRESIDENT: Robert W. Lennon

SECRETARY/TREASURER:

Laura Morrison

Jim Aquino

Frank Bua

Dick Dadey

Nick Debs

Joy Episalla

Kevin Goetz

Roy Gulick, M.D.

Jameel Jiwani

Richard Lynn, Ph.D., M.P.H.

Robert Monteleone

Eddie Pelto

David Sigal

Mrinal Vikram

2020 STAFF

EXECUTIVE DIRECTOR:

Mark Harrington

DEPUTY EXECUTIVE DIRECTOR:

Erica Lessem

TB PROJECT OFFICER:

David Branigan

TB PROJECT CO-DIRECTOR:

Mike Frick

STATE AND LOCAL POLICY DIRECTOR:

Annette Gaudino

HCV PROJECT DIRECTOR:

Bryn Gay

FINANCE MANAGER:

Christopher George

DIRECTOR OF FINANCE AND OPERATIONS:

Sabrina Guerrero-Morris

BASIC SCIENCE, VACCINES, AND CURE PROJECT DIRECTOR:

Richard Jefferys

HIV PROJECT DIRECTOR:

Jeremiah Johnson

GRANT OFFICER:

Jason Kirk

GOVERNMENT RELATIONS AND POLICY OFFICER:

Elizabeth Lovingher

U.S. AND GLOBAL HEALTH POLICY DIRECTOR: Suraj Madoori

ADMINISTRATOR:

Joseph McConnell

TB PROJECT CO-DIRECTOR:

Lindsay McKenna

COMMUNICATIONS MANAGER:

Dorrit Walsh





Treatment Action Group

www.treatmentactiongroup.org

90 Broad Street, Suite 2503
New York, NY 10004
Tel 212.253.7922

tag@treatmentactiongroup.org

TAG is a nonprofit, tax-exempt
501(c)(3) organization.
EIN 13-3624785